P. Barnes

发表

Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.

C. Gilks, A. Magliocco, S. Nofech-Mozes, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fine‐needle aspiration cytology of mammary fibroadenoma: A comparison of ThinPrep® and cytospin preparations

P. Barnes, Thai Yen Ly, R. Macintosh, 2010, Diagnostic cytopathology.

Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)

C. Gilks, M. Tsao, C. Cheung, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

Testing for her2 in breast cancer: current pathology challenges faced in Canada.

B. Gilks, A. Mulligan, A. Magliocco, 2012, Current oncology.

Inter-institutional pathology consultations for breast cancer: impact on clinical oncology therapy recommendations

D. Rayson, E. Grunfeld, P. Barnes, 2010, Current oncology.

Ten years of breast screening in the Nova Scotia Breast Screening Program, 1991-2001. experience: use of an adaptable stereotactic device in the diagnosis of screening-detected abnormalities.

G. Porter, Joy N Borgaonkar, J. Caines, 2005, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

Benign and Malignant Male Breast Diseases: Radiologic and Pathologic Correlation

N. Sinha, S. Iles, P. Barnes, 2015, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

Impact of Detection Method and Age on Survival Outcomes in Triple‐Negative Breast Cancer: A Population‐Based Cohort Analysis

D. Rayson, M. Abdolell, P. Barnes, 2018, Clinical breast cancer.

HER2 testing in metastatic breast cancer - Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?

D. Rayson, G. Bethune, P. Barnes, 2022, Annals of diagnostic pathology.

Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry

G. Bethune, P. Barnes, S. Godwin, 2021, Virchows Archiv.

CytoLyt® Fixation and Decalcification Pretreatments Alter Antigenicity in Normal Tissues Compared With Standard Formalin Fixation

P. Barnes, Kelly Dakin Haché, Jennette R. Gruchy, 2015, Applied immunohistochemistry & molecular morphology : AIMM.

Postirradiation pseudosclerodermatous panniculitis with involvement of breast parenchyma: a dramatic example of a rare entity and a pitfall in diagnosis

N. Walsh, P. Barnes, R. Rutledge, 2016, Journal of cutaneous pathology.

Application of the Probabilistic Approach to Reporting Breast Fine Needle Aspiration in Males

P. Barnes, J. Merrimen, R. Macintosh, 2008, Acta Cytologica.

Survivin and COX-2 expression in male breast carcinoma.

D. Rayson, R. Dewar, T. Younis, 2009, Breast.

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

Chao Li, Gang Han, Marius Ilie, 2019, Modern Pathology.

Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray

D. Rayson, R. Dewar, T. Younis, 2007, Breast Cancer Research and Treatment.

Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sections for immunohistochemistry.

B. Clarke, C. Gilks, C. Cheung, 2014, American journal of clinical pathology.

Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.

B. Gilks, B. Perez-Ordonez, P. Swanson, 2010, American journal of clinical pathology.

Implementation of a Canadian External Quality Assurance Program for Breast Cancer Biomarkers: An Initiative of Canadian Quality Control in Immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry

Richard Berendt, Louis Gaboury, Anthony Magliocco, 2009, Applied immunohistochemistry & molecular morphology : AIMM.

Barnes PJ, Boutilier R, Chiasson D, Rayson D.. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat 91: 173-178

D. Rayson, R. Boutilier, P. Barnes, 2005 .

Metaplastic breast carcinoma: clinical–pathologic characteristics and HER2/neu expression

D. Rayson, R. Boutilier, P. Barnes, 2005, Breast Cancer Research and Treatment.

Predictors of Outcome in Mammary Adenoid Cystic Carcinoma

P. Williams, A. Mulligan, Z. Kos, 2019, The American journal of surgical pathology.

Well‐differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in‐situ hybridization testing?

G. Bethune, P. Barnes, A. Pettit, 2017, Histopathology.

Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer

F. O'Malley, L. Gaboury, A. Magliocco, 2007, Current oncology.

Using Deep Learning to Predict Final HER2 Status in Invasive Breast Cancers That are Equivocal (2+) by Immunohistochemistry

G. Bethune, Alexi P. Surette, P. Barnes, 2022, Applied immunohistochemistry & molecular morphology : AIMM.

Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins

G. Porter, J. Caines, P. Barnes, 2005, Journal of surgical oncology.

Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force

A. Mulligan, Z. Kos, F. Lu, 2023, Current oncology.

Assessing breast cancer risk within the general screening population: developing a breast cancer risk model to identify higher risk women at mammographic screening

M. Abdolell, J. Caines, S. Iles, 2020, European Radiology.

Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study.

D. Rayson, M. Abdolell, T. Younis, 2011, Clinical breast cancer.

Isolated Tumor Cells in Sentinel Lymph Nodes of Primary Invasive Breast Carcinoma: A Cohort Analysis.

D. Rayson, G. Bethune, Manolhas Karkada, 2019, Clinical breast cancer.

Metastatic Mammary Carcinoma Presenting as a Large Cystic Axillary Mass: A Report of an Unusual Case.

P. Barnes, Allison Maybank, H. Curtis, 2023, International journal of surgical pathology.

Patterns of trastuzumab use and cost in a single Canadian cancer institute

D. Rayson, K. Potvin, T. Younis, 2005 .

B. Gilks, P. Swanson, C. Otis, 2010, American journal of clinical pathology.

Predicting Ki67, ER, PR, and HER2 Statuses from H&E-stained Breast Cancer Images

Nilanjan Ray, G. Bigras, P. Barnes, 2023, ArXiv.

HER2 testing in metastatic breast cancer - Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?

D. Rayson, G. Bethune, P. Barnes, 2022, Annals of diagnostic pathology.